Cellyan Biotechnology Co., Ltd. - Form 20-F Summary
Business Context and Reporting Period
Company: Cellyan Biotechnology Co., Ltd. (formerly Hong Kong Pharma Digital Technology Holdings Limited)
Reporting Period: Fiscal year ended March 31, 2026
Jurisdiction: Cayman Islands (Holding Company); Operations primarily in Hong Kong
Business Model: The Company provides OTC pharmaceutical cross-border e-commerce supply chain services and procurement/distribution services. It operates through two main divisions: Supply Chain Services (Joint Cross Border Logistics) and Procurement and Distribution (V-Alliance Technology Supplies).
Listing: Class A Ordinary Shares trade on Nasdaq Capital Market under symbol "HKPD".
Key Financial Metrics (Fiscal Year Ended March 31, 2026)
| Metric | 2026 (USD) | 2025 (USD) | Change |
|---|---|---|---|
| Total Revenue | $13,433,507 | $20,313,818 | (34%) |
| Gross Profit | $1,386,309 | $2,415,159 | (43%) |
| Gross Margin | 10.3% | 11.9% | -1.6 pts |
| Net Loss | $(1,135,963) | $(27,056) | Worsened |
| Cash & Equivalents | $221,841 | $748,721 | (70%) |
| Working Capital | $9,107,627 | N/A | N/A |
| Total Debt (Bank Loans) | $877,904 | $1,875,355 | (53%) |
Note: The filing text does not provide a clear value for "Working Capital" in 2025, though it states the 2026 figure is $9,107,627.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 34% to $13.4 million. Supply Chain Services revenue dropped 39% to $7.6 million due to weakened customer demand and intensified competition. Procurement and Distribution revenue fell 22% to $5.9 million, partly due to a strategic decision to discontinue business with low-margin customers.
- Profitability Deterioration: The Company moved from a net loss of $27,056 in 2025 to a net loss of $1.14 million in 2026. Gross margin compressed from 12% to 10% as the Company lowered selling prices to remain competitive.
- Expense Increase: Selling, general, and administrative (SG&A) expenses increased 8% to $2.4 million, driven by professional service and investor relations costs associated with maintaining Nasdaq listing status.
- Customer Concentration: Dependence on major customers remains high. Two customers accounted for 12.05% and 10.50% of total revenue in 2026. CaiNiao (Alibaba Group affiliate) remains a key partner, though revenue concentration from CaiNiao decreased slightly from 12.33% in 2025 to 10.50% in 2026.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Uncertainty: The independent auditor has included a "Material Uncertainty Related to Going Concern" paragraph in their report. This is due to the net loss of $1.1 million, net cash outflows from operating activities of $0.8 million, and a material decline in revenue. Management asserts that working capital and subsequent proceeds from fund liquidation ($1.4 million received in June 2026) are sufficient for the next 12 months.
- Nasdaq Delisting Risk: The Company received a notice from Nasdaq on January 12, 2026, regarding failure to maintain the $1.00 minimum bid price requirement. Nasdaq granted an extension until January 11, 2027, to regain compliance. Failure to comply could result in delisting.
- Capital Raising: In March 2026, the Company completed a private placement raising approximately $6.5 million through the issuance of Class A Ordinary Shares and warrants. Proceeds are intended for business expansion and working capital.
- Internal Control Weaknesses: The Company identified material weaknesses in internal controls over financial reporting, including insufficient accounting personnel with IFRS/SEC knowledge and lack of formal accounting policies. Remediation plans are underway.
- Regulatory Risks: Significant risks exist regarding operations in Hong Kong and Mainland China, including potential changes in PRC laws affecting cross-border e-commerce, data security, and the ability to transfer funds. The Company is also subject to risks related to the Hong Kong National Security Law.
Key Facts for Investor Verification
- Liquidity Position: Verify the sufficiency of the $221,841 cash balance on hand against the $0.8 million operating cash outflow and the $1.4 million subsequent fund liquidation proceeds to confirm the 12-month going concern assessment.
- Nasdaq Compliance: Monitor the Company's progress in regaining compliance with the $1.00 minimum bid price requirement by the January 11, 2027 deadline to assess delisting risk.
- Customer Concentration: Assess the stability of the relationship with CaiNiao and the top two customers, who collectively represent over 22% of revenue.
- Internal Controls: Review the status of remediation efforts for the identified material weaknesses in internal financial controls.
- Revenue Trends: Evaluate whether the 34% revenue decline is a temporary market fluctuation or a structural shift in the cross-border OTC pharmaceutical supply chain market.